What is Claimed is:

1. Use of fasoracetam in the preparation of a medicament for treating conduct disorder in a subject determined to have at least one genetic alteration in a metabotropic glutamate receptor (mGluR) network gene, wherein an effective amount of fasoracetam is to be administered to the subject, thereby treating conduct disorder and improving conduct disorder symptoms.

2. The use according to claim 1, wherein the presence of the genetic alteration is obtained after performance of a genetic screen.

3. The use according to claims 1 or 2, wherein the genetic alteration is a copy number variation (CNV).

4. The use according to claim 3, wherein the CNV is a deletion or a duplication.

5. The use according to any one of claims 1-4, wherein fasoracetam is to be administered at a dose of 50-400 mg, 100-400 mg, or 200-400 mg, and wherein the dose is to be administered once, twice, or three times daily.

6. The use according to any one of claims 1-5, wherein the patient treated has antisocial personality disorder.

7. The use according to any one of claims 1-6, wherein the subject is between the ages of 5 and 17, 5 and 8, 8 and 17, 8 and 12, 12 and 18, 13 and 18, or 12 and 17.

8. The use according to any one of claims 1-7, wherein the fasoracetam is to be administered in combination with another pharmaceutical or non-pharmaceutical therapy.

9. The use according to claim 8, wherein fasoracetam is to be administered in combination with an antipsychotic agent.

10. The use according to any one of claims 1-9, wherein symptoms of inattentiveness, hyperactivity, and/or impulsiveness are reduced in the subject after

at least 1 week, such as at least 2 weeks, at least 3 weeks, or at least 4 weeks of treatment with fasoracetam.

11. The use according to any one of claims 1-10, wherein symptoms of aggression or antisocial behavior are reduced in the subject after at least 1 week, such as at least 2 weeks, at least 3 weeks, or at least 4 weeks of treatment with fasoracetam.

12. The use according to claim 1, wherein at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 mGluR network genes are assessed for the presence of a CNV.

13. The use according to claim 1, wherein at least 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all of Tier 1 mGluR network genes are screened for the presence of a CNV.

14. The use according to claim 1, wherein at least 50, at least 100, at least 150, at least 175, or all of Tier 2 mGluR network genes are screened for the presence of a CNV.

15. The use according to claim 1, wherein at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, or all of Tier 3 mGluR network genes are screened for the presence of a CNV.

16. The use according to claim 1, wherein at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all of Tier 1 mGluR network genes; and at least 50, at least 100, at least 150, at least 175, or all

of Tier 2 mGluR network genes; and at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, or all of Tier 3 mGluR network genes are assessed for the presence of a CNV.

17. The use according to any one of the preceding claims, wherein the subject has conduct disorder as well as one or more of ADHD, ODD, anxiety disorder, Tourette syndrome, phobia, or depression.

18. The use according to any one of the preceding claims, wherein the subject has one or more of the following phenotypic changes after at least 1 week, such as at least 2 weeks, at least 3 weeks, or at least 4 weeks of treatment with fasoracetam:

(a) the subject has difficulty controlling anger and the anger control symptoms are improved;

(b) the subject has disruptive behaviors and the disruptive behaviors are reduced;

(c) the subject's CGI-I is reduced by at least 1 or by at least 2; the subject's CGI-I score after one, two, three, or four weeks of treatment is 1 or 2;

(d) the subject's CGI-S score after one, two, three, or four weeks of treatment is 1; the subject's ADHD Rating Scale score is reduced by at least 25%, such as at least 30%, at least 35%, or at least 40%;

(e) the subject has symptoms of inattentiveness and the inattentiveness symptoms are reduced; the subject has symptoms of hyperactivity and the hyperactivity symptoms are reduced;

(f) the subject has symptoms of impulsiveness and the impulsiveness symptoms are reduced;

(g) the subject has symptoms of ODD such as anger and irritability, argumentation and defiance, and/or vindictiveness and the ODD symptoms are reduced;

(h) the subject has symptoms of anxiety and the anxiety symptoms are reduced;

(i) the subject has symptoms of Tourette's syndrome, and the Tourette's syndrome symptoms are reduced;

(j) the subject has symptoms of autism, and the autism symptoms are reduced; and

(k) the subject has symptoms of movement disorder and the movement disorder symptoms are reduced.